http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2345357-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4433 |
| filingDate | 1999-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_332a55a832eee4cdd2451ee4880a360c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6909d3c6003cd397015916e17d6e9ffa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b03cfd29aea37b549d7c422f85c04589 |
| publicationDate | 2000-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2345357-A1 |
| titleOfInvention | Benzimidazolinyl piperidines as cgrp ligands |
| abstract | A compound of formula I, wherein: R1 is naphthyl or benzothienyl which is unsubstituted or substituted at up to three substitutable positions independently by C1-6 alkyl, halogen, C1-6 alkoxy, CF3, OCF3, NO2, CN, methylenedioxy or ethylenedioxy; R2 is hydrogen, C1-8 alkyl, -(CH2)t-aryl wherein aryl is selected from phenyl, biphenyl and naphthyl, -(CH2)t-heteroaryl wherin heteroaryl is selected from tetrazolyl, oxadiazolyl, thiadiazolyl, triazolyl and pyrazinyl, -(CH2)qC(O)OR6, -(CH2)qOR6, -(CH2)qOC(O)R6, -(CH2)qC(O)R6, -(CH2)qC(O)(CH2)taryl, -(CH2)qN(R6)C(O)R6, -(CH2)qC(O)N(R6)2, -(CH2)qN(R6)SO2R6, -(CH2)qN(R6)C(O)N(R6)2, -(CH2)qOC(O)N(R6)2, -(CH2)qN(R6)C(O)OR6, -(CH2)qN(R6)SO2N(R6)2 and -(CH2)qS(O)mR6; R3 is NH2; R4 is hydrogen, C1-6 alkyl, C1-6 alkoxy, halogen, OCF3 or CF3; R5 is hydrogen, C1-6 alkyl, C1-6 alkoxy, halogen, OCF3 or CF3; R6 is hydrogen, C1-8 alkyl or C3-7 cycloalkyl, and when two R6 groups are present and both represent C1-8 alkyl they may optionally together with the atom to which they are both attached form a C3-8 ring; Q is -(CH2)x-C(R7)(R7a)-(CH2)y-or -(CH2)x-V-(CH2)y-; R7 and R7a are independently chosen from hydrogen, CF3, halogen, C1-6 alkyl and C1-6 alkoxy; V is a C3-8 non-aromatic cyclic or bicyclic ring or an aromatic ring which is benzene or naphthalene, said ring being unsubstituted or substituted at up to three substitutable positions independently by C1-6 alkyl, C1-6 alkoxy, halogen, OCF3, CF3, CN, NO2, methylenedioxy or ethylenedioxy; m is 0, 1 or 2; q is 0, 1, 2, 3 or 4; t is 0, 1, 2 or 3; x and y are independently 0, 1, 2, 3 or 4; or a pharmaceutically acceptable salt thereof; useful as CGRP (calcitonin gene-related peptide) receptor ligands, processes for their preparation, their use in therapy, pharmaceutical compositions comprising them and methods of treatment using them. |
| priorityDate | 1998-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 196.